Systimmune
Updates & Highlights
PMLiVE · 21 days ago
Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate
PR Newswire · 22 days ago
SystImmune Reports Phase 1 Data for BL-M14D1 Demonstrating Promising Activity in Small-Cell Lung Cancer at ASCO
BriefGlance · about 1 month ago
SystImmune's ADC Pipeline Shines Ahead of ASCO with Major Cancer Data
Recent Openings
View all 1 jobs arrow_forwardAll Jobs
Culture & Mission
Benefits & Perks
Health Insurance
Medical, dental & vision
Learning Budget
Professional development
Generous PTO
Paid time off
Competitive Salary
Market-rate compensation
Equity/Stock Options
Ownership in the company
Remote Work
Work from anywhere flexibility
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Systimmune?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentBristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate
Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate
PMLiVE · 21 days ago
SystImmune Reports Phase 1 Data for BL-M14D1 Demonstrating Promising Activity in Small-Cell Lung Cancer at ASCO
SystImmune Reports Phase 1 Data for BL-M14D1 Demonstrating Promising Activity in Small-Cell Lung Cancer at ASCO
PR Newswire · 22 days ago
SystImmune's ADC Pipeline Shines Ahead of ASCO with Major Cancer Data
SystImmune's ADC Pipeline Shines Ahead of ASCO with Major Cancer Data
BriefGlance · about 1 month ago
SystImmune expands its iza-bren programme again | ApexOnco - Clinical Trials news and analysis
SystImmune expands its iza-bren programme again | ApexOnco - Clinical Trials news and analysis
Oncology Pipeline · about 1 month ago
SystImmune starts another first-line phase 3 | ApexOnco - Clinical Trials news and analysis
SystImmune starts another first-line phase 3 | ApexOnco - Clinical Trials news and analysis
Oncology Pipeline · 3 months ago
SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Extensive Stage Small Cell Lung Cancer at ELCC 2026
SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Extensive Stage Small Cell Lung Cancer at ELCC 2026
PR Newswire · 3 months ago
Systimmune’s iza-bren hits phase III breast cancer goals in China
Systimmune’s iza-bren hits phase III breast cancer goals in China
BioWorld News · 4 months ago
Bristol Myers, SystImmune post late-stage trial win for breast cancer drug
Bristol Myers, SystImmune post late-stage trial win for breast cancer drug
Seeking Alpha · 4 months ago
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast ...
Business Wire · 4 months ago
ESMO 25: Biokin/SystImmune’s BsADC Doubles ORR/PFS Vs Chemo In NPC
ESMO 25: Biokin/SystImmune’s BsADC Doubles ORR/PFS Vs Chemo In NPC
Citeline News & Insights · 8 months ago
SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO
SystImmune Announces iza-bren Meets One of the Dual Primary Endpoints in the BL-B01D1-303 Trial in Recurrent or Metastatic NPC Patients with Results Presented as a Late-Breaking Oral Presentation at ESMO
PR Newswire · 8 months ago
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025
PR Newswire · 8 months ago
SystImmune to Receive $250M BMS Milestone
SystImmune to Receive $250M BMS Milestone
Contract Pharma · 8 months ago
SystImmune receives $250 million milestone payment from Bristol Myers Squibb
SystImmune receives $250 million milestone payment from Bristol Myers Squibb
Investing.com · 8 months ago
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration
PR Newswire · 8 months ago
SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform
SystImmune, Inc. to Present New Clinical Data on Izalontamab Brengitecan and BL-M07D1 Highlighting Strength of Differentiated Antibody Drug Conjugate (ADC) Platform
PR Newswire · 9 months ago
SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025
SystImmune, Inc. to Present New iza-bren (izalontamab brengitecan) Data in Non-Small Cell Lung Cancer at WCLC Congress 2025
PR Newswire · 10 months ago
FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug
FDA awards breakthrough therapy status to BMS and SystImmune’s NSCLC drug
Pharmaceutical Technology · 10 months ago
Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan...
Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan...
Medical Dialogues · 10 months ago
SystImmune, Inc. to Present New izalontamab brengitecan (iza-bren) Data in Small Cell Lung Cancer and Non-Small Cell Lung Cancer with Driver Genomic Alterations (GA) outside of Classic EGFR Mutations at ASCO Congress 2025
SystImmune, Inc. to Present New izalontamab brengitecan (iza-bren) Data in Small Cell Lung Cancer and Non-Small Cell Lung Cancer with Driver Genomic Alterations (GA) outside of Classic EGFR Mutations at ASCO Congress ...
PR Newswire · about 1 year ago